ncRNA basic information
ncRNA ID:
NR_026941.1
ncRNA Database:
RefSeq
ncRNA Name:
CASC2c
ncRNA Type:
lncRNA
ncRNA Expression:
up-regulated
ncRNA Method:
RT-qPCR
ncRNA Target Gene:
NA
ncRNA Pathway:
ERK1/2 and Beta-catenin signaling pathways
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB00515 (APRD00359)
Drug Name:
Cisplatin
Drug Method:
The expression of CASC2c in NSCLC tissues and cell lines was detected by real-time fluorescence quantitative PCR (RT-qPCR). MTT and Transwell assay were used to determine the proliferation and migration of NSCLC cells in the experimental group and the control group respectively. The drug sensitivity test was used to confirm whether increasing the CASC2c expression level could reverse the resistance of NSCLC cells to the chemotherapy drug cisplatin. The effects of CASC2c on the expression levels of p-ERK1/2 and Beta-catenin were detected by western blot.
Drug Response:
sensitive
Cancer basic information
Cancer:
lung non-small cell carcinoma
Tissue/Cell:
tissue and cell line (H292, H226, H1975, H460,BEAS-2B )
Other information
Title:
Effects of long non-coding RNA (lncRNA) cancer susceptibility candidate 2c (CASC2c) on proliferation, metastasis and drug resistance of non-small cell lung cancer (NSCLC) cells through ERK1/2 and Beta-catenin signaling pathways.
Journal:
Pathol Res Pract
Published:
2019
PubMed ID:
31300295